NASDAQ:STOK

Stoke Therapeutics - STOK Stock Forecast, Price & News

$13.26

-0.35 (-2.57%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $12.82
▼
$13.46
50-Day Range: $12.56
▼
$22.53
52-Week Range: $9.55
▼
$33.06

Volume: 225,159 shs
Average Volume: 288,533 shs
Market Capitalization: $522.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.83

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 238.1% Upside
$44.83 Price Target
Short Interest: Bearish
24.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.59
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.69) to ($2.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

632nd out of 1,072 stocks

Pharmaceutical Preparations Industry

297th out of 534 stocks

3.5

Analyst's Opinion

Consensus Rating
Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.83, Stoke Therapeutics has a forecasted upside of 238.1% from its current price of $13.26.
Amount of Analyst Coverage
Stoke Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
24.18% of the float of Stoke Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Stoke Therapeutics has a short interest ratio ("days to cover") of 24.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Stoke Therapeutics has recently decreased by 1.50%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Stoke Therapeutics does not currently pay a dividend.
Dividend Growth
Stoke Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Stoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Stoke Therapeutics is -0.59.

2.7

News and Social Media Coverage

News Sentiment
Stoke Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
Search Interest
Only 2 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stoke Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.70% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.69) to ($2.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stoke Therapeutics is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stoke Therapeutics is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stoke Therapeutics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

August 25, 2022 | markets.businessinsider.com

Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study

August 25, 2022 | finance.yahoo.com

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

August 19, 2022 | finance.yahoo.com

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

August 10, 2022 | finance.yahoo.com

How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91%

August 10, 2022 | msn.com

Michael O'Neill out but not down as Stoke City suffer shoot-out defeat at Morecambe

August 10, 2022 | msn.com

Furious families wake up to find red and blue paint splatters on their Stoke homes and cars

August 10, 2022 | msn.com

'Disgraceful' - Furious Michael O'Neill reveals talks after Stoke City defeat

August 10, 2022 | msn.com

Morecambe boss makes Stoke City claim and red card comment

August 9, 2022 | nasdaq.com

Stoke Therapeutics (NASDAQ:STOK) shareholders are up 47% this past week, but still in the red over the last three years

August 8, 2022 | nasdaq.com

Stoke Therapeutics Posts Wider Loss In Q2

July 6, 2022 | uk.finance.yahoo.com

Stoke Therapeutics, Inc. (STOK)

June 3, 2022 | bizjournals.com

Coming out was a necessary step

June 1, 2022 | finance.yahoo.com

Scientist needed to come out as gay before founding a biotech

June 1, 2022 | finance.yahoo.com

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 12, 2022 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK shareholders incur further losses as stock declines 15% this week, taking one-year losses to 64%

May 2, 2022 | finance.yahoo.com

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

April 7, 2022 | finance.yahoo.com

Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

April 5, 2022 | finance.yahoo.com

Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

March 25, 2022 | seekingalpha.com

ADPT, SGMO and RDBX among after hour movers

March 10, 2022 | seekingalpha.com

Stoke Therapeutics GAAP EPS of -$0.66 misses by $0.04

March 10, 2022 | benzinga.com

Recap: Stoke Therapeutics Q4 Earnings

March 10, 2022 | finance.yahoo.com

Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

February 28, 2022 | finance.yahoo.com

Wall Street Analysts Believe Stoke Therapeutics, Inc. (STOK) Could Rally 184%: Here's is How to Trade

February 28, 2022 | finance.yahoo.com

Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

February 10, 2022 | finance.yahoo.com

Wall Street Analysts See a 192% Upside in Stoke Therapeutics, Inc. (STOK): Can the Stock Really Move This High?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Company Calendar

Last Earnings: 8/08/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STOK
CUSIP: N/A
CIK: 1623526
Web: www.stoketherapeutics.com
Phone: (781) 430-8200
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $44.83
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $38.00
Forecasted Upside/Downside: +238.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-85,810,000.00
Net Margins: N/A
Pretax Margin: -1,546.24%
Return on Equity: -41.91%
Return on Assets: -34.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.46
Quick Ratio: 10.46

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.92 per share
Price / Book: 2.24

Miscellaneous

Outstanding Shares: 39,419,000
Free Float: 34,413,000
Market Cap: $522.70 million
Optionable: Not Optionable
Beta: 0.64

Key Executives

Dr. Edward M. Kaye M.D. (Age 73)
Ph.D., CEO & Director
Comp: $938.37k

Dr. Adrian R. Krainer Ph.D. (Age 63)
Co-Founder, Independent Director & Member of Scientific Advisory Board
Comp: $89k

Mr. Stephen J. Tulipano CPA (Age 63)
CPA, MBA, Chief Financial Officer
Comp: $617.07k

Dr. Barry S. Ticho FACC (Age 61)
M.D., Ph.D., Chief Medical Officer
Comp: $664.99k

Ms. Isabel Aznarez Ph.D. (Age 49)
Co-Founder & Group VP of Discovery Research

Dr. Huw M. Nash Ph.D. (Age 55)
COO & Chief Bus. Officer

Mr. Jonathan Allan J.D.
Gen. Counsel

Ms. Dawn Kalmar (Age 44)
Chief Communications Officer

Ms. Joan Wood
Chief HR Officer

Ms. Shamim Ruff (Age 62)
Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.
What is Stoke Therapeutics' stock price forecast for 2022?: 5 brokers have issued 12-month target prices for Stoke Therapeutics' stock. Their STOK share price forecasts range from $38.00 to $50.00. On average, they anticipate the company's share price to reach $44.83 in the next year. This suggests a possible upside of 238.1% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.
How have STOK shares performed in 2022?: Stoke Therapeutics' stock was trading at $23.99 at the start of the year. Since then, STOK stock has decreased by 44.7% and is now trading at $13.26.
View the best growth stocks for 2022 here.
When is Stoke Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our STOK earnings forecast.
How were Stoke Therapeutics' earnings last quarter?: Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings data on Monday, August, 8th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.07. The company earned $3.23 million during the quarter, compared to analysts' expectations of $2.71 million.
What other stocks do shareholders of Stoke Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?: (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is Stoke Therapeutics' stock symbol?: Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."
How do I buy shares of Stoke Therapeutics?: Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Stoke Therapeutics' stock price today?: One share of STOK stock can currently be purchased for approximately $13.26.
How much money does Stoke Therapeutics make?: Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $522.70 million. The company earns $-85,810,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.
How many employees does Stoke Therapeutics have?: The company employs 102 workers across the globe.
How can I contact Stoke Therapeutics?: Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Stoke Therapeutics - STOK Stock Forecast, Price & News

Stoke Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Stoke Therapeutics (NASDAQ:STOK) Stock

STOK Stock News Headlines

STOK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

STOK Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™